Journal article
The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, BJ Kuss, CS Tam, Z Gasztonyi, F Offner, S Lunin, F Bosch, MS Davids, N Lamanna, U Jaeger, P Ghia, F Cymbalista, CA Portell, AP Skarbnik Show all
Blood | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase d and g (PI3K-d,g) being developed for treatment of hematologic malignancies. PI3K-d,g signaling can promote B-cell proliferation and survival in clonal B-cell malignancies, such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In a phase 1 study, duvelisib showed clinically meaningful activity and acceptable safety in CLL/SLL patients. We report here the results of DUO, a global phase 3 randomized study of duvelisib vs ofatumumab monotherapy for patients with relapsed or refractory (RR) CLL/SLL. Patients were randomized 1:1 to oral duvelisib 25 mg twice daily (n 5 160) or ofa..
View full abstractGrants
Funding Acknowledgements
This work was supported by Verastem Oncology and Infinity Pharmaceuticals Inc.